Form 4: Zymeworks CEO Kenneth Galbraith Executes Stock Transactions Following RSU Vesting

Zymeworks CEO Kenneth Galbraith acquired and sold shares of common stock on January 6, 2025, following the vesting of restricted stock units, with sales primarily covering tax obligations.

Summary

• On January 6, 2025, Zymeworks CEO Kenneth Galbraith engaged in transactions involving the company's common stock.
• These transactions included the acquisition of 47,666 shares and 66,666 shares of common stock upon the vesting of restricted stock units (RSUs) granted in 2023 and 2024 respectively.
• Simultaneously, Mr. Galbraith sold 23,885 and 33,406 shares of common stock at a weighted average price of $14.9241 per share.
• The sales were primarily to cover tax withholding obligations and other fees associated with the vesting of the RSUs.
• The reported transactions resulted in Mr. Galbraith holding 80,803 shares of common stock after the sales.

Sentiment

Score: 5

Explanation: The document reflects routine transactions related to executive compensation and does not indicate any positive or negative sentiment. It is a neutral event.

Industry Context

This is a routine filing related to executive compensation and is common for companies that use stock-based compensation. It does not indicate any specific trend in the biotechnology industry.

Comparison to Industry Standards

• Stock transactions following RSU vesting are a common practice among publicly traded companies, particularly in the biotech sector.
• Many companies use 'sell to cover' provisions to manage tax obligations for employees receiving stock-based compensation.
• The price range of $14.44 to $15.14 is within the expected range for stock transactions of this nature, and is not unusual compared to other companies in the sector.

Stakeholder Impact

• The transactions have a minimal impact on shareholders as they are routine and related to executive compensation.
• The sales were not discretionary and were required to cover tax obligations, so they do not indicate a change in management's view of the company's prospects.

Key Dates

Keywords

Zymeworks, Kenneth Galbraith, stock transactions, restricted stock units, RSU vesting, insider trading, tax obligations, common stock